Speaker illustration

Professor William Herrington

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

Member of:

European Society of Cardiology

Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He jointly leads the Renal Studies Group which he joined in 2010 as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). He is Chief Investigator of the EMPA-KIDNEY trial which tested the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. The trial has now entered a post-trial observational follow-up phase and is developing health economic analyses. He is on a number of clinical practice guideline working groups, and co-chairs the UK Kidney Association guideline group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease. He is also interested in renal epidemiology, trial methodology and has chaired the UK Renal Trials Network since 2020.

Chronic kidney disease and diabetes

Event: ESC Congress 2023

Topic: Diabetes and the Heart

Session: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb